Stoke Therapeutics (STOK) Chief Medical Officer Ticho Barry Sells 7,176 Shares

What Happened
Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), sold a total of 7,176 shares on August 3, 2026 in two dispositions. The filings report disposals of 5,907 shares at a weighted average price of $28.95 (proceeds $171,008) and 1,269 shares at a weighted average price of $29.45 (proceeds $37,377), for combined gross proceeds of approximately $208,385. These were sales (S) — often routine cashing-out rather than an expressed buy signal.

Key Details

• Transaction date: August 3, 2026; Form 4 filed August 5, 2026 (filed within the typical 2-business-day window).
• Shares sold: 5,907 shares @ $28.95 (reported weighted avg; actual per-share prices ranged $28.36–$29.35) and 1,269 shares @ $29.45 (reported weighted avg; actual per-share prices ranged $29.36–$29.54).
• Total shares sold: 7,176; total reported proceeds: ~$208,385.
• Plan/footnotes: Sale executed pursuant to a Rule 10b5-1 trading plan adopted November 19, 2025 (footnote F1). Footnotes F2 and F3 note the reported prices are weighted averages and give the per-share price ranges; the filer will provide per-price breakdowns on request.
• Shares owned after transaction: Not disclosed in the information provided in this summary (not included in the details supplied).
• Transaction type code: S = Sale (open market/private sale reported).

Context
A Rule 10b5-1 plan indicates these sales were executed pursuant to a pre-established trading arrangement, which can make the timing less informative about the insider’s current view of the company. For retail investors, purchases generally carry more weight as signals than routine sales; this filing documents routine selling under an established plan and does not, by itself, indicate new material information about company prospects.